AR038849A1 - Uso de ribozimas en la deteccion de agentes adventicios - Google Patents

Uso de ribozimas en la deteccion de agentes adventicios

Info

Publication number
AR038849A1
AR038849A1 ARP030100637A ARP030100637A AR038849A1 AR 038849 A1 AR038849 A1 AR 038849A1 AR P030100637 A ARP030100637 A AR P030100637A AR P030100637 A ARP030100637 A AR P030100637A AR 038849 A1 AR038849 A1 AR 038849A1
Authority
AR
Argentina
Prior art keywords
reovirus
composition
ribozyme
ribozimas
adventive
Prior art date
Application number
ARP030100637A
Other languages
English (en)
Spanish (es)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR038849A1 publication Critical patent/AR038849A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121Hammerhead
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/30Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/337Ribozyme
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
ARP030100637A 2002-02-28 2003-02-26 Uso de ribozimas en la deteccion de agentes adventicios AR038849A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36073002P 2002-02-28 2002-02-28

Publications (1)

Publication Number Publication Date
AR038849A1 true AR038849A1 (es) 2005-01-26

Family

ID=27766245

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100637A AR038849A1 (es) 2002-02-28 2003-02-26 Uso de ribozimas en la deteccion de agentes adventicios

Country Status (16)

Country Link
EP (2) EP1481084B1 (cg-RX-API-DMAC7.html)
JP (3) JP4369243B2 (cg-RX-API-DMAC7.html)
AR (1) AR038849A1 (cg-RX-API-DMAC7.html)
AT (1) ATE519860T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003206587B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307882A (cg-RX-API-DMAC7.html)
CA (1) CA2374388C (cg-RX-API-DMAC7.html)
DE (1) DE03704136T1 (cg-RX-API-DMAC7.html)
DK (1) DK1481084T3 (cg-RX-API-DMAC7.html)
ES (1) ES2241506T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008277A (cg-RX-API-DMAC7.html)
NZ (1) NZ534488A (cg-RX-API-DMAC7.html)
TR (1) TR200501513T3 (cg-RX-API-DMAC7.html)
TW (1) TWI329132B (cg-RX-API-DMAC7.html)
WO (1) WO2003072811A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200406231B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306959C (zh) * 2004-09-21 2007-03-28 中国科学院武汉病毒研究所 草鱼呼肠孤病毒抗原亚单位疫苗制备方法
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TWI597499B (zh) * 2009-05-28 2017-09-01 亞培生物股份有限公司 體外病原體檢驗技術

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
WO1994001549A1 (fr) 1992-07-02 1994-01-20 Sankyo Company, Limited Ribozyme bouclee en epingle a cheveux
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
AU682854B2 (en) 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
EP1486211B1 (en) 1993-04-30 2008-10-22 Wellstat Biologics Corporation Compositions for treating cancer using viruses
AU5334294A (en) * 1993-10-15 1995-05-04 Dkfz Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Asymmetric hammerhead ribozymes and nucleotide sequences for their construction
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
HUP0003911A3 (en) 1997-10-09 2007-11-28 Pro Virus Treatment of neoplasms with viruses
US6307041B1 (en) 1998-03-28 2001-10-23 University Of Utah Research Foundation Circular, hairpin, circular/hairpin, lariat, and hairpin-lariat hammerhead ribozymes
WO2000024912A1 (en) * 1998-10-23 2000-05-04 The Children's Medical Center Corporation Use of a self-cleaving rna motif to modulate gene expression
WO2001072964A2 (en) * 2000-03-27 2001-10-04 Smithkline Beecham Corporation Detection of viable agents
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
DE03704136T1 (de) 2005-12-15
TW200404099A (en) 2004-03-16
ZA200406231B (en) 2005-11-30
JP5615865B2 (ja) 2014-10-29
ES2241506T3 (es) 2011-12-13
JP2012125257A (ja) 2012-07-05
HK1067664A1 (en) 2005-04-15
TR200501513T3 (tr) 2005-06-21
JP2005518797A (ja) 2005-06-30
JP4369243B2 (ja) 2009-11-18
WO2003072811A2 (en) 2003-09-04
EP1481084A2 (en) 2004-12-01
TWI329132B (en) 2010-08-21
JP2009005712A (ja) 2009-01-15
ES2241506T1 (es) 2005-11-01
EP2439286A1 (en) 2012-04-11
NZ534488A (en) 2008-04-30
AU2003206587B2 (en) 2007-03-15
AU2003206587A1 (en) 2003-09-09
EP1481084B1 (en) 2011-08-10
CA2374388C (en) 2005-07-12
BR0307882A (pt) 2004-12-28
MXPA04008277A (es) 2004-11-10
DK1481084T3 (da) 2011-09-26
WO2003072811A3 (en) 2004-02-05
ATE519860T1 (de) 2011-08-15
CA2374388A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
MX2021011419A (es) Un codificador, un decodificador y métodos correspondientes para la intrapredicción.
ES2190727B1 (es) Dispositivo para formar y/o aumentar el numero relativo de celulas indiferenciadas en una poblacion celular y procedimientos correspondientes.
UY29873A1 (es) Composición de detergente liquido
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
CO5271708A1 (es) Ensayo y metodos basados en el uso de canales de sodio como objetivos de amiloide b o de sus agregados
SV2002000343A (es) Composisiones farmaceuticas de inhibidores de la glucogeno fosforilasa ref. pc10882/20147/bb
BR0215405A (pt) Composições e processos de uso de collajolie
CL2009000843A1 (es) Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
CL2008001072A1 (es) Bloque de limpieza de inodoro que es al menos parcialmente transparente o translucida, que comprende 2 - 50% de material biocida y 50 - 98% de composicion portadora que comprende 5 - 50% de agente jabon, 30 - 90% de humectante, 5 - 30% de solvente; metodo para proporcionar higiene en un inodoro; y uso del bloque
AR110174A2 (es) Agentes endoparasiticidas y procedimiento de preparación
AR038849A1 (es) Uso de ribozimas en la deteccion de agentes adventicios
ECSP077920A (es) Dispositivo de ensayo
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ECSP055718A (es) Composicion limpiadora que contiene un polimero hidrofilizado
CL2012002871A1 (es) Metodo para identificar una población de celulas tr1 en reposo que comprende la deteccion de la expresion en la superficie celular de los marcadores cd4, cd25, cd127 y cd62l; poblacion aislada de celulas tr1; metodo para disminuir una poblacion de celulas tr1; kit para identificar o aislar una poblacion de celulas tr1 en reposo y/o activadas; composicion farmaceutica que comprende una poblacion de celulas tr1 en reposo y/o activadas.
AR025995A1 (es) Metodo para determinar la presencia de leptina o de agentes mimeticos de leptina y vector que incluye la secuencia de nucleotidos que codifican la region del promotor ang-2
BR0007284A (pt) Método para medir a concentração de um polìmero anionicamente carregado em uma solução aquosa, e, solução reagente
AR031383A1 (es) Metodo de dosificacion in vitro de la fibrina soluble por generacion de productos de degradacion especificos, un testigo positivo utilizable en dicho metodo, utilizacion de un activador de plasminogeno de fuerte afinidad para un metodo de dosificacion de la fibrina soluble, un equipo de dosificacion
AR023194A1 (es) Agente antiincrustante que contiene thiacloprid
ES2194996T3 (es) Composiciones y metodos para desinfectar una lente de contacto y detectar la presencia de un desinfectante oxidativo.
AR031404A1 (es) Una composicion y metodo de aplicacion
GT200600522A (es) Nueva asociación de un inhibidor de la corriente sinusal i, y de un inhibidor de la enzima de conversión y las composiciones farmacéuticas que la contienen
AR044641A1 (es) Composicion blanqueadora
Hagihara et al. An experimental study about survey response rate Basic study of efficient strategies to raise the participation rate of Mobility Management
CR8973A (es) Composicion farmaceutica en forma de una forma de dosificacion solida soluble en agua

Legal Events

Date Code Title Description
FB Suspension of granting procedure